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Abstract
Background:  The literature abounds with increasing numbers of research studies using genomic data in combination with health
data (eg, health records and phenotypic and lifestyle data), with great potential for large-scale research and precision medicine.
However, concerns have been raised about social acceptability and risks posed for individuals and their kin. Although there has
been public engagement on various aspects of this topic, there is a lack of information about public views on data access models.
Objective:  This study aimed to address the lack of information on the social acceptability of access models for reusing genomic
data collected for research in conjunction with health data. Models considered were open web-based access, released externally
to researchers, and access within a data safe haven.
Methods:  Views were ascertained using a series of 8 public workshops (N=116). The workshops included an explanation
of benefits and risks in using genomic data with health data, a facilitated discussion, and an exit questionnaire. The resulting
quantitative data were analyzed using descriptive and inferential statistics, and the qualitative data were analyzed for emerging
themes.
Results:  Respondents placed a high value on the reuse of genomic data but raised concerns including data misuse, information
governance, and discrimination. They showed a preference for giving consent and use of data within a safe haven over external
release or open access. Perceived risks with open access included data being used by unscrupulous parties, with external release
included data security, and with safe havens included the need for robust safeguards.
Conclusions:  This is the first known study exploring public views of access models for reusing anonymized genomic and health
data in research. It indicated that people are generally amenable but prefer data safe havens because of perceived sensitivities.
We recommend that public views be incorporated into guidance on models for the reuse of genomic and health data.
(J Med Internet Res 2019;21(8):e14384)  doi: 10.2196/14384
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Introduction
Background
We are witnessing a rapid expansion in the availability and
use of genomic data to inform research and clinical care. The
trajectory is for this trend to increase with the falling cost
of whole-genome sequencing, rapid technical advances, and
rise of data management facilities [1]. Work with genomic
data spans the whole spectrum, from large-scale research
using many thousands of records to precision medicine at
the individual level. To date, the majority of genomic data
have been used in large-scale research such as genome-
wide association studies (GWAS) and exome-wide association
studies (EWAS), among others. GWAS and EWAS are
essential observational studies comparing DNA sequences and
exploring variants that may be associated with a phenotypic
trait. Precision medicine, where treatments and medication
regimes are informed by individual genetic status, seeks to
use the findings of observational studies to inform tailored
clinical care. There are strong drivers for precision medicine,
such as reducing the use of poorly effective interventions,
thereby leading to better patient outcomes and saving costs.
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The UK Chief Medical Officer has expressed her dream for
genomic medicine to become commonplace: “I want the NHS
across the whole breadth to be offering genomic medicine -
that means diagnosis of our genes - to patients where they
can possibly benefit” [2]. The Department of Health program
seeking to sequence 100,000 genomes has achieved this target,
thereby creating a valuable data resource toward this goal [3].
The US National Institute of Health has initiated a program
called All of Us, aiming to gather data from at least 1 million
citizens to accelerate the introduction of precision medicine
into all areas of health and health care on a large scale [4].
The Canadian government has made a major investment to
advance cutting-edge developments in genomics research [5].
Successes in precision medicine are growing, but there is much
further work to be done to gain the advantages and for it to
become mainstream.
Between the ends of the spectrum, large scale studies
using genomic data and precision medicine using individual
genomic information, there is a vast range of work and many
permutations of research to enable meaningful findings to
be taken forward. With the exception of certain single-gene
conditions such as cystic fibrosis and sickle cell anemia,
the relationship between genotype and phenotype is highly
complex, involving multiple genes and expression profiles.
Research using genomic data in conjunction with health data
(defined here as health records, phenotypic data, and lifestyle
data) in condition-specific cohorts or population-level studies
plays a unique role. In this type of research, it is often genomic
derivatives (eg, variants and risk scores) rather than sequence
data that are used with health data. Such studies allow the
relationships between genomic markers, lifestyle factors, and
phenotypes of interest to be explored. However, for this
research to take place, genomic data collected for research
studies need to be available for reuse. To be most effective, the
data need to be linkable at the individual level so that genomic
and wider factors can be taken into account.
There are some prevalent concerns about social acceptability
and the risks posed for individuals and their kin in
the use of genomic data for research. These include
possible discrimination in relation to insurance coverage and
employment opportunities for people with genetic conditions
or high perceived risks of developing a disease [6]. However,
public views on the use of genomic data have been found to
be variable. The Global Alliance for Genomics and Health
(GA4GH) has been running a public survey extending across
numerous countries seeking views on the use of genomic data
[7]. Among over 10,000 respondents, 52% felt information
from DNA was different from other medical data, with 48%
unsure or making no distinction. In relation to web-based
data, respondents considered their banking data as needing
most protection, above medical and genomic information [8].
However, although there is public engagement on various
aspects of this topic, there is a lack of information about
public views on models of data access. From a review
on published studies using genomic data (to be published
separately), we categorized 3 main data access models: open
access where data are publicly available on a website, curated
data released to specified researchers, and data accessed by
specified researchers within a safe haven. We define a data
safe haven as a secure virtual environment within which data
are managed and analyzed and from which anonymized results
can be released [9].
Study Aim
To date, the majority of extant genomic data have been
collected for research studies; the reuse of these datasets in
deidentified form formed the focus of our study. The main aim
of this study was to address the lack of information on the
social acceptability of access models for reusing genomic data
collected for research in conjunction with health data. This
included public views on the use of the data with informed
consent, without informed consent, and without consent but
with notification for each of the 3 models. The reuse of any
genomic data collected for clinical care and incorporated into
the electronic health record (EHR) is out of scope for this
study. It is assumed that the sharing of EHR data is subject
to health provider mechanisms and agreements with recipient
parties in line with relevant jurisdictional legislation.
Methods
Study Design
The study used a mixed methods approach, collecting
and integrating quantitative and qualitative data. Public
views were ascertained using a series of 8 workshops held
between February and November 2018. Groups were selected
purposively on the basis of having an interest in health care,
health research, biological science, or data linkage research.
The reasoning for this was 2-fold: we wanted to gain the
views of groups with an interest in at least one of these areas
as the study was breaking new ground; and it meant that
we could tailor and reduce the explanation of concepts to
meet the needs of the audience in the time available for the
workshops. The groups comprised pupils at sixth-form college
(in Neath Port Talbot); students at a further education college
(in Pembrokeshire); university staff and students; a business
professionals group; a general public consumer panel; science
festival attendees, a grand round of health professionals;
and University of Third Age members. All workshops were
held in Wales, and where the location is not mentioned, the
meetings took place on Swansea University premises. As
the workshops took place at preexisting meetings with no
registration process, it was not possible to control the numbers
attending or influence participant selection.
Ethical approval for research with public participants was
obtained from the Swansea University Medical School
Research Ethics and Governance Committee. We note that in
working with the public, we generally referred to genetic data
rather than genomic, as genetics was a more familiar term to
the participants. We did, however, explain the terms and the
difference between them.
The workshops were led by KHJ and HD and ran for 1 hour.
Notes of the discussions were taken (by HD and KHJ) and
compared for consensus. The presentation of the study and
research examples was given by KHJ, who also initiated the
discussions. The information was presented in a deliberately
neutral way not to preempt or influence viewpoints. The
information was presented consistently across all workshops
with each following the same format.
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Initial Discussions on Public Knowledge
This involved asking the audience about the latest news item
they had heard about genetics, their awareness of genetic data
being used in research, and how they believe the data are used.
Introduction to the Study
This included describing the study purpose; the focus on
the reuse in deidentified form of genetic data collected for
research, as distinct from the process of data collection for
clinical purposes; types of genetic data and wider health data;
and how data can be accessed in terms of the 3 main models
(open access, released externally, or within a data safe haven).
We included a brief explanation of genetic data sequence and
derivatives such as traits, variants, and risk scores.
Examples of organizations operating differing access were
genetic and health data made openly available in the Personal
Genome Project [10], UK Biobank collates and releases
anonymized linked genetic and health data to approved
researchers for specific studies [11], and the Sax Institute
provides access to anonymized genetic and health data to
approved researchers for specific studies within a data safe
haven [12]. It was explained that, although data may be used
in anonymous form, identifiable data are needed to process
the primary research data for reuse and enable linkage to
health data. Through these examples, we provided practical
descriptions of each operating model, and how the ethical and
other regulatory permissions needed for researchers to access
the data can vary.
Participants were provided with examples of research studies
that have used genetic data, particularly with health data,
and arising from the commercial and noncommercial sectors.
Studies included large-scale work to identify variants of
interest, considering lifestyle factors in relation to the BRCA
mutations, and medication monitoring based on genetics. We
also included an introduction to direct-to-consumer genetic
testing companies, such as Patients Like Me [13] and 23andMe
[14], which provide sequencing services and personal genetic
information to individuals, then retain and use the resulting
data for research.
Discussions on Public Views
At this stage in the workshop, an open discussion was
encouraged by asking the audience how they felt about these
kinds of research taking place and what could be done to
address any concerns they have.
Exit Questionnaire
Participants were asked to complete a questionnaire at the
end of the workshop (Multimedia Appendix 1). This asked
about knowledge and views on the use of genetic data and
specifically asked about the relative acceptability of the 3
models of access. The questionnaire data were collected in
anonymized form, and it gave the participants the opportunity
to provide their views individually and privately.
Quantitative responses to the questionnaire were analyzed
in IBM SPSS (version 22). Descriptive statistics were used
to characterize the respondents, and for frequencies, the
chi-square test was used to assess independence between
categories, and the two-proportion z-test was used to compare
proportions with Bonferroni correction where appropriate
[15]. Free-text qualitative responses from the questionnaire
were analyzed thematically by manual assessment and
comparison between members of the research team (HD
and KHJ) for consensus on theme identification and data
convergence. A similar thematic analysis was conducted on
the topics arising in the open discussions. Most analyses were
based on the questionnaire responses, with the information
from the open discussions being used more generally for
context setting.
Results
Overview
The initial discussions (step 1) on public knowledge raised
topics from news stories such as 3-parent babies and designer
babies, heritable genetic conditions such as Huntingdon
disease, the potential for cancer research, gene editing,
and invasive testing of embryos for genetic problems.
Participants perceived the great value and opportunities
becoming available with the increasing use of genetic data.
These benefits were reiterated in the open discussion (step
3), but participants also drew attention to various concerns
about privacy and confidentiality depending on data use
and parties concerned. These included statements such as,
“I would be worried about being discriminated against
(insurance, work etc.),” “I am fearful of data in the hands of
commercial companies,” and “I’m concerned about legislative
and attitudinal ‘creep’—what we enforce now will, no doubt
creep over time.” In terms of what could be done to address
their concerns, participants highlighted the need for robust
governance, data anonymization, data security, and greater
transparency in data use.
Characterizing the Respondents
Information about the attendees was collected in part A of
the questionnaire shown in Multimedia Appendix 1. There
were 116 respondents in total: 54 men and 62 women. The
denominator in all percentage values is 116 unless otherwise
stated. The age profile was as follows: 16 to 25 years: 18.9%
(22/116); 26 to 35 years: 31.8% (37/116); 36 to 45 years:
15.5% (18/116); 46 to 55 years: 9.4% (11/116); 56 to 65 years:
6.8% (8/116); and older than 65 years: 17.2% (20/116). As
the data were collected in age bands, mean age and standard
deviation are not known. This profile was compared with the
2011 UK census figures [16] to gauge representativeness of
the sample. The age bands are slightly different in the census
but are close enough to provide an indicative measure. From
this, we observed that our sample was overrepresented in the
26 to 35 year age band. Among the respondents, 50 (43.1%,
50/116) had children, and the remainder did not. Just more than
half (n=58, 52%) held a degree with almost one-third (n=32,
33%) holding a degree in a biological subject. This higher rate
than in the general population was to be expected because of
the nature of the groups. By comparison, approximately 40%
of the UK population are graduates [17].
Participants were asked to gauge their own background
knowledge of genetics in 5 categories from none to very
good. This was a matter of personal perception of one’s own
ability, and as a general summary, the frequencies were no
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knowledge: 6.8% (8/116); a little: 34.4% (40/116); middling:
36.2% (42/116); good: 14.6% (17/116); and very good: 6.8%
(8/116). This was examined further by taking into account
the highest education level of the respondents in a biological
subject and separately in any subject. All the qualifications are
UK based, apart from degrees and professional qualifications,
which are more generic categories: General Certificate of
Secondary Education (GCSE) examinations are taken at
age 16 years, Advanced Level (A level) examinations are
taken at 18 years, Higher National Certificate/Diploma
qualifications are often taken in post-16 Further Education
colleges, and National Vocational Qualifications are work-
based examinations. When all the categories of education
level in Q5a or Q5b were included, there was no association
between attainment level and self-reported knowledge. This
may have been because of the variability between the
categories of qualification. However, when the categories
were restricted to those known to be hierarchical (GCSE,
A level, and degree), attainment in a biological subject was
found to be associated with higher self-reported knowledge
(chi-squared P=.02). The relationship between self-reported
knowledge and attainment across all subjects remained
insignificant.
Respondents’ Views on Data Use
The majority (78/116, 67.2%) of questionnaire respondents
placed a high or very high value on using genetic data
for research, with only 8 people (7/116, 6.8%) considering
the value to be low or very low. No specific definition of
value was presented to allow participants to make their own
interpretations. Placing higher value on the use of genetic
data was associated with higher attainment in a hierarchical
biological subject (chi-square P=.005) and all subjects (chi-
square P=.02).
There was no association between levels of value of using
genetic data and levels of concern across all respondents.
The most frequent level of concern about the use of genetic
data for research was moderate, with 53/116 people (48%)
indicating this response, 38/116 people (34%) showing low or
very low concern, and 20/116 people (19%) having high or
very high concern. The level of concern was not associated
with educational attainment in either a biological subject
or other subjects. It was also not associated with age or
workshop attended. It was, however, associated with gender,
with women showing higher levels of concern than men
(chi-squared P=.01). A variety of themes emerged from the
free-text responses in relation to causes for concern (Table
1), with the most frequent being misuse of data tied with
concerns about information governance. Respondents noted
that their concerns would be allayed if they could be assured
of appropriate data use, data security, and proper information
governance to avoid the data falling into the hands of agents
who might discriminate against them.
Table 1.  Concerns about the use of genetic data for research (N=116).
Type of concern Respondents, n (%) Percentage of total concerns
Data misuse 30 (25.9) 23
Information governance 30 (25.9) 23
Purpose of use 23 (19.8) 18
Discrimination 22 (19.0) 17
Security 16 (13.8) 13
Disclosure risk 7 (6.0) 6
Respondents’ concerns about the use of genetic data for
research are given in themed areas. Each participant was asked
to provide up to 3 concerns, which were then grouped into
themes.
The questionnaire asked participants to provide their views on
access to their genetic data in each of the 3 main access models:
openly accessible on a website, released to researchers, and
access within a data safe haven. For each option, they
were asked to indicate whether they were willing, not sure,
or unwilling in relation to whether they were consented,
not consented, or not consented but notified. The results
of analyzing these categorical data are shown in Figure 1.
Participants showed a preference for informed consent over
the other options and a preference for data use within a
safe haven compared with other access models. A similar,
but more cautious, pattern was observed for the use of data
pertaining to participants’ children. Interestingly, less than 5%
of respondents stated they would be unwilling for their genetic
data to be reused in a data safe haven if they were asked for
consent to do so.
For each model, attendees indicated their willingness for their
data to be used with consent, without being consented, and
notified.
The significance of the apparent differences was tested by
comparing the proportions of respondents willing for their data
to be reused across consent options within each data access
model (ie, intramodel seen horizontally in Figure 1). Similarly,
we compared the proportions willing between models of data
access (ie, intermodel seen vertically in Figure 1). We repeated
these 2 analyses for willingness for children’s data reuse. We
also compared proportions willing for the use of their own
and their children’s data by access model for a given consent
status.
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Figure 1.  Participant views on access to their and their children’s genetic data in each of the three main access models.
Intramodel Comparison of Data Access Preferences
We found that there was a significant difference between
willingness for the reuse of respondents’ genetic data with
versus without consent and with consent versus notified within
all 3 access models. This was the case with and without the
Bonferroni correction. There was, however, no significant
difference in the proportion of respondents willing for their
data to be reused between the options of without consent and
notified. The same pattern was observed in their willingness
for their children’s data to be reused (Table 2). This indicates
that the respondents’ preferences are to be consented to the
reuse of genomic data collected for research. It was not
considered appropriate for reuse of genomic research data to
proceed without consent, nor sufficient to be merely notified.
Table 2.  Intramodel comparison: with consent, without consent, and notified.
With consent: without consent With consent: notified Without consent: notifiedConsent status—access model
P valuea CI P valuea CI P valuea CI
Open: own ≤.001 0.33 to 0.56 ≤.001 0.29 to 0.52 .40 −0.13 to 0.05
Open: children ≤.001 0.17 to 0.41 ≤.001 0.18 to 0.42 .81 −0.10 to 0.08
Release: own ≤.001 0.34 to 0.58 ≤.001 0.31 to 0.56 .72 −0.09 to 0.13
Release: children ≤.001 0.27 to 0.54 ≤.001 0.25 to 0.52 .70 −0.10 to 0.14
DSHb: own ≤.001 0.46 to 0.68 ≤.001 0.34 to 0.58 .09 −0.02 to 0.24
DSH: children ≤.001 0.22 to 0.51 ≤.001 0.18 to 0.47 .57 −0.01 to 0.17
aP values above .05 were not considered significant.
bDSH: data safe haven.
This table displays comparisons of respondent preferences
between consent options within each of the 3 models of data
access: openly accessible, released externally to researchers,
and accesses within a safe haven. Preferences in relation to
their own and children’s data are shown. The significance level
is 95%. The CIs are the interval lower and upper limits for
the difference in proportions using the two-proportion z-test.
Frequency denominators varied between questions with none
less than 100 (of 116 participants) and were used accordingly.
A Bonferroni correction was applied (for 3 tests in each set,
thus requiring a P value <.017 to remain significant at the 95%
level), but in this case, it did not affect the results.
Intermodel Comparison of Data Access Preferences
We found no significant differences in respondents’
willingness for their genomic data to be reused when the
open access model was compared with the release model.
The results were similarly not significant between the release
model and access within a data safe haven, with the
Bonferroni correction. The same pattern was seen for the reuse
of children’s data. There were, however, some significant
differences between the open access and data safe haven
models, corresponding with the greater degree of respondent
concern about data being openly accessible compared with
accessed within a safe haven (Table 3).
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Table 3.  Intermodel comparison: open access, release, and within data safe haven.
Open: release Open: DSHa Release: DSHAccess model—consent status
P valueb CI P valueb CI P valueb CI
With consent: own .11 −0.24 to 0.02 <.001 0.13 to 0.37
.02c 0.02 to 0.26
With consent: children .14 −0.04 to 0.26
.01c 0.05 to 0.34 .27 −0.07 to 0.24
Without consent: own .07 −0.01 to 0.19
.02c 0.02 to 0.23 .60 −0.08 to 0.15
Without consent: children .21 −0.04 to 0.17
.04c 0.01 to 0.24 .39 −0.07 to 0.18
Notified: own .17 −0.03 to 0.18 .001 0.08 to 0.31 .06 0.00 to 0.24
Notified: children .06 0.00 to 0.21 .004 0.06 to 0.29 .30 −0.06 to 0.20
aDSH: data safe haven.
bP values above .05 were not considered significant.
cNot significant when Bonferroni correction applied.
This table displays comparisons of respondent preferences
between access models for each of the 3 consent options: with
consent, without consent, and without consent but notified.
Preferences in relation to their own and children’s data are
shown. The conditions for the two-proportion z-test and
Bonferroni correction were as for Table 2. Some results were
no longer significant when adjusting for multiple testing.
Own Versus Childrens’ Data Reuse Comparison
The comparisons showed no significant differences in the
reuse of respondents’ own against children’s data for any
model when the options were without consent or without
consent but notified. As can be seen from Figure 1, the
proportions of respondents willing for their, or their children’s,
data to be reused under these options were low. There were
some differences in willingness for the reuse of respondents’
own against children’s data when the option was with consent.
However, the only 1 remaining significant after Bonferroni
correction was reuse within a data safe haven. This was
the model favored by the respondents with a greater degree
of caution seen in relation to the reuse of children’s data
compared with their own (Table 4).
Table 4.  Comparison between the use of own and children’s data by access model for a given consent status.
With consent—own: children Without consent—own: children Notified—own: childrenConsent status—access model
P valuea CI P valuea CI P valuea CI
Open
.027b 0.02 to 0.30 .94 −0.09 to 0.09 .27 −0.04 to 0.15
Release
.033b 0.01 to 0.29 .62 −0.09 to 0.14 .66 −0.09 to 0.15
DSHc .002 0.08 to 0.34 .92 −0.12 to 0.13 .27 −0.06 to 0.21
aP values above .05 were not considered significant.
bNot significant when Bonferroni correction applied.
cDSH: data safe haven.
Respondent preferences between the use of their own and
children’s data by access models and consent option are
shown. The conditions for the two-proportion z-test and
Bonferroni correction were as for Table 2. Most results
were not significant, and this was further reduced when the
Bonferroni correction was applied.
Respondents’ Reasons for Viewpoints
Participants elaborated on reasons for their views in relation
to each model. Their free-text viewpoints provided context
to the numerical data. Their main concerns included data
security, protection of identity, the right to make informed
choices, control over data use, who might access the data
under the various models, and concern about unknown
future developments. Example responses for each of the
access models (openly accessible, data released externally to
researchers, and data accessed within a data safe haven) from
a variety of participants are given below. Information about
each respondent has been included for context.
In relation to data being openly accessible, viewpoints
included the following:
Potential for re-identification by unscrupulous
people/organisations. [female, aged 16-25 years, no
children, A level in a biological subject, professional
qualification in another subject, data use: high value
and moderate concern]
[I am] sufficiently unhappy with the idea that it
would be an active deterrent from having children
at all/going abroad to have them. [male, aged
26-35 years, no children, degree in a biological
subject, data use: moderate value and very high
concern]
It’s not my place to give info of my children to
strangers for any reason. [male, aged 26-35 years,
has children, degree in a biological subject, data use:
very high value and low concern]
...want to help with research...my DNA can’t be used
to re-identify me yet. [female, aged 16-25 years, no
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children, GCSE in a biological subject, data use:
high value, low concern]
In relation to data released externally, viewpoints included the
following:
I don’t know enough about it [but] I’d like to
help researchers find cures and things. [female,
aged 16-25 years, no children, GCSE in a
biological subject, data use: moderate value,
moderate concern]
My primary concern is the security of data if it is
sent out to researchers. [male, aged >65 years, has
children, degree in a biological subject, data use:
very high value, low concern]
If going to researchers, then it is less likely to
be abused by others online etc. who are not
researchers. [male, aged 46-55 years, has children,
professional qualification in a biological subject,
data use: moderate value and low concern]
Not sure if people could be identified [female, aged
26-35 years, no children, degree in a biological
subject, data use: very high value and moderate
concern]
In relation to data accessed within a safe haven, viewpoints
included the following:
[Data used] to what end is my main concern. But
overall happier in a safer environment. [male, aged
26-35 years, no children, A level in a biological
subject, degree in another subject, data use: very
high value and low concern]
I fully expect this to be used—missing a trick
otherwise. [female, aged 36-45 years, has children,
degree in a biological subject, data use: high value
and moderate concern]
I would want to be reassured of safeguards. [female,
aged 26-35 years, has children, A level in a
biological subject, degree in another subject, data
use: very high value and moderate concern]
Happy for my data to be used as I’m and adult and
I’m told. Not for my children. They need to be able
to make that decision. [male, aged 26-35 years, has
children, GCSE in a biological subject, degree in
another subject, data use: very high value and low
concern]
The viewpoints reflected the workshop discussions being
premised on the use of genetic data with wider health data in
line with the focus of our study, but we included a question (in
the questionnaire) to ask specifically about views on genetic
data use linked with health record data to clarify any additional
views. Many of the participants’ viewpoints expressed were
the same or similar to their previous responses; however, some
expressed stronger concerns, and none were less concerned.
Where additional views were given, they further polarized the
preference for consent and data reuse in a safe haven.
In relation to linked genetic and wider health data being openly
accessible in anonymized form, participant views included the
following:
Scholars need these websites to check their daily
work
Fine as long as there is consent
I would need to see what the data looks like. There
are too many concerns for me to agree to this
I feel it’s not safe and I don’t want the discrimination
For the release of linked anonymized genetic and wider health
data, responses included the following:
I do not mind as long as it is anonymous
Acceptable as long as there is consent and data is
held securely
Dependent on the research question and access
limitations
Unsure—would depend on safeguards imposed
For accessing linked anonymized genetic and wider health
data in a safe haven, viewpoints included the following:
Most comfortable with this
Safe, secure, governance, auditable—okay
Data being used by verified researchers for public
benefit is a good thing. Having the data kept safe
and controlled is a must
I am happy for this to happen provided it is safe, not
sold etc
Discussion
Principal Findings
This study has begun to address the lack of knowledge on
the social acceptability of access models for reusing genomic
data collected for research in conjunction with wider health
data. This is the first known study to address this topic.
As noted earlier, it does not relate to the reuse of genomic
data collected for clinical care, incorporated into the health
record. Our findings indicate that most public participants
place a high to very high value on the reuse of genomic
data. This viewpoint was associated with higher educational
attainment in a biological subject but was also present across
all educational subjects. Their areas of concern included
data misuse, how data are governed, disclosure risk, possible
discrimination, and the purpose of data use and were in
accord with the large-scale survey conducted by the GA4GH
[7,8]. Levels of concern were not, however, associated with
educational attainment but were associated with gender with
women showing greater concern than men. This might be due,
in part, to the fact that women show greater levels of anxiety
than men in the general population [18].
A comparison of response frequencies indicated that
participants preferred to give informed consent for the reuse
of their own or children’s genomic data that had been
collected for research, over being notified or not consented.
Tests of statistical significance between without consent and
without consent but notified suggest the respondents saw
little difference between these 2 options and bolstered the
preference for consent. Participants favored data use within
a safe haven compared with the release and open access
models in terms of response frequencies. However, this
JOURNAL OF MEDICAL INTERNET RESEARCH Jones et al
http://www.jmir.org/2019/8/e14384/ J Med Internet Res 2019 | vol. 21 | iss. 8 | e14384 | p. 8
(page number not for citation purposes)
difference was only significant between the open access and
safe haven models of data access. Free-text responses provided
information on reasons for preferences. These included the
desire to support research but strong views against open
access, which go some way to explaining the observed results.
Although there was little statistical significance, participants
expressed more caution in relation to children’s data than their
own in terms of the response frequencies on access model
and consent options and their elaborations on reasons for their
choices. Respondents felt it was important that children are
able to make their own choices in relation to the reuse of their
genomic data. In practice, this depends on the age of valid
consent but supports the reconsenting of young people once
that age is attained. However, we also acknowledge that this
might not always be practicable and propose that participants
coming of age should always be taken into account at the outset
so that it can be accommodated in the research plans.
We have limited this study to public views on the reuse
of genomic data collected for research because this is
the main source of extant genomic data and because the
sharing of data contained in the health record is subject to
health provider data governance, including repurposing in
line with jurisdictional legislation. There are numerous long-
established enterprises across the world that reuse population
health data in anonymized form for research, using datasets
drawn from existing health records rather than engaging in
primary data collection [19]. We recognize this as distinct
from data collected for research and are not making any
recommendations in relation to the work of these enterprises
other than to state that an insistence on additional consent for
the reuse of health record data would be impractical and highly
detrimental to such research [20].
The use of genomic data through web-based open access is
current practice in large-scale GWAS and EWAS because
of the compute capacity required in processing the data files
and the need to access data across multiple sources [21].
GWAS and EWAS often use genomic data without associated
wider health data because they are concerned with profiling
variants of possible significance [22]. We acknowledge the
indispensable value of such studies, such as for sequence
alignment and variant calling. The GA4GH has proposed a
system of registered access for web-based use of genomic data
with health data to facilitate the reuse of data within the bounds
of consent restrictions and other ethical obligations [23]. We
welcome this as an improvement, as our findings with little
favor for sharing genomic data through open web-based access
suggest that open access would not be socially acceptable as an
extensible model for research linking genomic to wider health
data. Release to specified researchers or especially access
within a data safe haven was preferred and also reflects the
general trend in working with linked health data [9].
Limitations
We recognize the limitations of our study. The sample size
was relatively small but included a range of ages, interest
areas, and backgrounds. In the interests of privacy, we did
not collect the full demographic details of our participants,
and having grouped age into 10-year bands, we could not drill
down further on this variable. The sample size also meant
that we were limited in our options for stratified analyses.
The workshops took place across South Wales, and although
we do not know if public opinion on the reuse of genomic
data with other health data would be significantly different
in other parts of the United Kingdom or wider world, we
acknowledge location as a possible limitation. As noted, we
also acknowledge that a greater number of our participants
were educated to degree level than the general population.
However, further work could be undertaken to expand the
study and address this possible source of bias in the opinions
expressed. We have not included a consideration of legal and
ethical requirements and how they vary, as we are preparing a
further publication to do these issues justice and keep the focus
of this paper on public views.
Recommendations for Future Work
The reuse of genomic data with health data is an expanding
area and one that needs much further work with the public
and other stakeholders. Although our participants expressed
a preference for consent, there are questions around the
purpose and nature of the consent. If the data are to be reused
in anonymized form, then strictly speaking, consent is not
required for that reuse. But identifiable data are necessary
to create anonymized data, thus calling for consent for data
processing into anonymized form. This would need to be made
clear on the participant information sheet and in the consent
process.
We recommend that consent for the reuse of research data
be incorporated into the consent form at data collection to
avoid subsequent difficulties with reuse. The lead author has
proposed this to the UK Health Research Authority for all
primary research using personal data, not limited to genomic
data. It is being taken forward as advice to be given to
researchers by ethics committees and institutional review
boards as part of the UK integrated research application
system. Example wording for the participant information sheet
and consent form is given in Multimedia Appendix 2. This
is being piloted and has begun to see acceptance by research
ethics committees [24]. This simple idea has the potential to
revolutionize data reuse by avoiding the lack of appropriate
consent. However, we also acknowledge that consent is not
the ultimate panacea [25], particularly with the degree of
unknownness in genomic data. Further work on consent for
reuse needs to ensure the public properly understand this
characteristic of genomic data.
Recommendation 1: The inclusion of consent to use personal
data for deidentification so data can be reused for research
should be incorporated into consent forms and participant
information sheets for studies collecting primary data.
Biobanks commonly use a broad consent model where
participants agree to a framework for future research of
certain types. In the past, this involved the use of biological
samples, but in this genomic era, it also involves the use of
data generated from the samples, thus raising greater privacy
concerns for individuals and their kin [6]. Dynamic consent
usually involves recontacting individuals to ask consent for
particular uses [26]. Although there seem to be pros and
cons with each, it would be difficult to enact a meaningful
dynamic consent model for the reuse of data in anonymized
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form because the whole point of reusing data in this form is
to protect (and not know) identity. But this too needs further
exploration with the public and other stakeholders.
Recommendation 2: Public engagement should be conducted
on a range of consent models to gain viewpoints on the
acceptability of models for the reuse of genomic and
health data, taking into account ethical and legal issues,
and practicalities such as research utility and computing
constraints.
The GA4GH proposal for registered access to web-based
genomic and health data is a novel development and one
requiring an assessment of public views to gauge its relative
acceptability. This could follow a similar model as we have
used here and could take into account factors such as types
of research, parties accessing the data, requirements and
constraints on data processing, compute capacity, and the pros
and cons of other access models.
Recommendation 3: Public engagement should be conducted
on the acceptability of registered access to web-based genomic
and health data, in comparison with other access options and
conditions.
As the use of genomic data is still relatively new, the level
of public awareness needs to be enhanced to enable people
to make informed choices. This should include a balanced
explanation of the known perils and promise of genetic
research and precision medicine and should be conducted
transparently in a 2-way dialog, acknowledging that there are
unknowns. This is also true for many health professionals,
hence the rise in Genomic Medicine education. We also
propose that education on this subject begins early by being
properly incorporated into curricula for secondary school
pupils (aged 11#18 years) to enable current and future
generations to make informed choices.
Recommendation 4: Greater efforts are needed to raise
awareness, engage in public dialog, and improve education
about the perils and promise of genetic data research and
precision medicine.
Genomic data are not singled out from other health data in
data protection legislation (at least in the European Union)
[27], and it is important not to bias public opinion and stifle
research by exceptionalizing the risks in reusing genomic data
[28]. Nonetheless, it is imperative that robust safeguards are in
place so that genetic privacy and confidentiality (including in
relation to kin) are secured. We propose that there is a need for
a risk-based model incorporating public views into a flexible
suite of controls to protect identities and maximize data utility.
Recommendation 5: Public views should be incorporated into
the development of a risk-based, flexible suite of controls for
accessing genomic and health data for research.
Conclusions
There is undoubtedly great potential in the use of genomic and
health data for large-scale research and precision medicine.
However, concerns about social acceptability and the risks
posed for individuals and their kin need to be addressed.
Although there is much public engagement on health data
sharing in general and on various aspects of genomic data
reuse, there has been a lack of information about public
views on models for accessing combined genomic and health
data. To date, most extant genomic data have been collected
for research studies, and these datasets formed the focus of
our study. This is the first known study to explore public
views of access models for reusing anonymized genomic
and health data in research. It indicated that people are
generally amenable but prefer data safe havens over external
release to specified researchers and over open access because
of perceived sensitivities. We recommend further public
engagement, and that public views be incorporated into
guidance on models for the reuse of genomic and health data.
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